Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1

Anti-Cancer Drugs

Volumn 17, Issue 8, 2006, Pages 891-903

  Chow, Warren A ^a   Guo, Song ^a   Valdes Albini, Frances ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Liposarcoma; Nelfinavir; Sterol regulatory element binding protein 1

Indexed keywords

AMPRENAVIR; CELL NUCLEUS ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; FAS ANTIGEN; INDINAVIR; NELFINAVIR; PROTEIN BAX; PROTEIN P53; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ADIPOCYTE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LIPOSARCOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV PROTEASE INHIBITORS; HUMANS; LIPOSARCOMA; NELFINAVIR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 33748474995     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000224448.08706.76     Document Type: Article

References (38)

1. Coindre J-M, Terrier P, Guillou L, Le Dousal V, Collin F, Ranchère D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Center Sarcoma Group. Cancer 2001; 91:1914-1926.
2. Brennan MF, Alektiar KM, Maki RG. Sarcomas of the soft tissue and bone. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles & practice of oncology. 6th ed. Philadelphia, PA: Lippincott-Raven; 2001. pp. 1841-1891.
3. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338:1281-1292.
4. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
5. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chishold DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus. Lancet 1999; 353:2093-2099.
6. Koefler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 2003; 9:1-9.
7. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev 1996; 10:1096-1107.
8. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109:1125-1131.
9. Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, et al. SREBP-1, a basic helix-loop-helix leucine zipper protein that controls transcription of the LDL receptor gene. Cell 1993; 75:187-197.
10. Hua X, Wu J, Goldstein JL, Brown MS, Hobbs HH. Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13. Genomics 1995; 25:667-673.
11. Hua X, Yokoyama C, Wu J, Briggs MR, Brown MS, Goldstein JL, Wang X. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci U S A 1993; 90:11603-11607.
12. Miserez AR, Cao G, Probst LC, Hobbs HH. Structure of the human gene encoding sterol regulatory element binding protein 2 (SREBF2). Genomics 1997; 40:31-40.
13. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997; 99:838-845.
14. Hua X, Nohturfft A, Goldstein JL, Brown MS. Sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein. Cell 1996; 87:415-426.
15. Sakai J, Nohturfft A, Goldstein JL, Brown MS. Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J Biol Chem 1998; 273:5785-5793.
16. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R, et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to Insig-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 2002; 110:489-500.
17. Duncan EA, Brown MS, Goldstein JL, Sakai J. Cleavage site for sterol-regulated protease localized to a Leu-Ser bond in the lumenal loop of sterol regulatory element-binding protein-2. J Biol Chem 1997; 272:12778-12785.
18. Rawson RB, Zelenski NG, Nijhawan D, Ye J, Sakai J, Hasan MT, et al. Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBP's. Mol Cell 1997; 1:47-57.
19. Hirano Y, Yoshida M, Shimizu M, Sato R. Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiqutin-proteasome pathway. J Biol Chem 2001; 276: 36431-36437.
20. Kotzka J, Müller-Wieland D, Koponen A, Njamen D, Kremer L, Roth G, et al. ADD1/SREBP-1c mediates insulin-induced gene expression linked to the MAP kinase pathway. Biochem Biophys Res Commun 1998; 249:75-79.
21. Kotzka J, Müller-Wieland D, Roth G, Kremer L, Munck M, Schürmann S, et al. Sterol regulatory element binding proteins SREBP-1a and SREBP-2 are linked to the MAP kinase cascade. J Lipid Res 2000; 41:99-108.
22. Roth G, Kotzka J, Kremer L, Lehr S, Lohaus C, Meyer HE, et al. MAP kinases Erk 1/2 phosphorylate sterol regulatory element-binding protein (SREBP)-1a at serine 117 in vitro. J Biol Chem 2000; 275:33302-33307.
23. Caron M, Auclair M, Vigourox C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50:1378-1388.
24. Zhang B, Macnaul K, Szalkowski D, Li Z, Berger J, Moller DE. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab 1999; 84:4274-4277.
25. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 2000; 275:41325-41332.
26. Gagnon A, Angel JB, Sorisky A. Protease inhibitors and adipocyte differentiation in cell culture. Lancet 1998; 352:1032-1038.
27. Nguyen AT, Gagonon AM, Angel JB, Sorisky A. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS 2000; 14:2467-2473.
28. Bastard J-P, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031.
29. Shimano H, Shimomura I, Hammer RE, Herz J, Goldstein JL, Brown MS, et al. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest 1997; 100:2115-2124.
30. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998; 12:3182-3194.
31. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Scand Suppl 1996; 413:2-28.
32. Wang H, Maechler P, Antinozzi PA, Herrero L, Hagenfeldt-Johansson KA, Björklund A, et al. The transcription factor SREBP-1c is instrumental in the development of b-cell dysfunction. Proc Natl Acad Sci U S A 2003; 278:16622-16629.
33. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268:1766-1769.
34. Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 1988; 61:420-427.
35. Juhasz A, Frankel P, Cheng C, Rivera H, Vishwanath R, Chiu A, et al. Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. J Clin Lab Anal 2003; 17:184-194.
36. Demetri GD, Fletcher CDM, Mueller E, Sarraf P, Naujoks R, Campbell N, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-g ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 1999; 96:3951-3956.
37. Amemiya-Kudo M, Shimano H, Yoshikawa T, Yahagi N, Hasty AH, Okazaki H, et al. Promoter analysis of the mouse sterol regulatory element-binding protein-1c gene. J Biol Chem 2000; 275:31078-31085.
38. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.